Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1980 Nov;30(2):462–466. doi: 10.1128/iai.30.2.462-466.1980

Effects of treatment with muramyl dipeptide and certain of its analogs on resistance to Listeria monocytogenes in mice.

R C Humphres, P R Henika, R W Ferraresi, J L Krahenbuhl
PMCID: PMC551335  PMID: 7439991

Abstract

Studies were carried out to determine whether treatment of mice with the synthetic adjuvant muramyl dipeptide (MDP) afforded any resistance to infection with Listeria monocytogenes. Regardless of the timing, dose, or route of administration, there was no evidence that treatment with either MDP or two of its analogs (des-MDP or MDP-D-D) induced any resistance to listeria infection in BALB/c, CBA/J, or C57BL/6J mice. In contrast, pretreatment with MDP induced marked protection to infection with Streptococcus pneumoniae (type III).

Full text

PDF
462

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Audibert F., Chédid L., Lefrancier P., Choay J. Distinctive adjuvanticity of synthetic analogs of mycobacterial water-soluble components. Cell Immunol. 1976 Feb;21(2):243–249. doi: 10.1016/0008-8749(76)90053-8. [DOI] [PubMed] [Google Scholar]
  2. Azuma I., Sugimura K., Taniyama T., Yamawaki M., Yamamura Y. Adjuvant activity of mycobacterial fractions: adjuvant activity of synthetic N-acetylmuramyl-dipeptide and the related compounds. Infect Immun. 1976 Jul;14(1):18–27. doi: 10.1128/iai.14.1.18-27.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chedid L., Audibert F., Lefrancier P., Choay J., Lederer E. Modulation of the immune response by a synthetic adjuvant and analogs. Proc Natl Acad Sci U S A. 1976 Jul;73(7):2472–2475. doi: 10.1073/pnas.73.7.2472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chedid L., Parant M., Parant F., Audibert F., Lefrancier F., Choay J., Sela M. Enhancement of certain biological activities of muramyl dipeptide derivatives after conjugation to a multi-poly(DL-alanine)--poly(L-lysine) carrier. Proc Natl Acad Sci U S A. 1979 Dec;76(12):6557–6561. doi: 10.1073/pnas.76.12.6557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chedid L., Parant M., Parant F., Lefrancher P., Choay J., Lederer E. Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs. Proc Natl Acad Sci U S A. 1977 May;74(5):2089–2093. doi: 10.1073/pnas.74.5.2089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Damais C., Parant M., Chedid L., Lefrancier P., Choay J. In vitro spleen cell responsiveness to various analogs of MDP (N-acetylmuramyl-L-alanyl-D-isoglutamine), a synthetic immunoadjuvant, in MDP high-responder mice. Cell Immunol. 1978 Jan;35(1):173–179. doi: 10.1016/0008-8749(78)90137-5. [DOI] [PubMed] [Google Scholar]
  7. Ellouz F., Adam A., Ciorbaru R., Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun. 1974 Aug 19;59(4):1317–1325. doi: 10.1016/0006-291x(74)90458-6. [DOI] [PubMed] [Google Scholar]
  8. Fevrier M., Birrien J. L., Leclerc C., Chedid L., Liacopoulos P. The macrophage, target cell of the synthetic adjuvant muramyl dipeptide. Eur J Immunol. 1978 Aug;8(8):558–562. doi: 10.1002/eji.1830080804. [DOI] [PubMed] [Google Scholar]
  9. Finger H., Wirsing von König C. H. Failure of synthetic muramyl dipeptide to increase antibacterial resistance. Infect Immun. 1980 Feb;27(2):288–291. doi: 10.1128/iai.27.2.288-291.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hadden J. W., Englard A., Sadlik J. R., Hadden E. M. The comparative effects of isoprinosine, levamisole, muramyl dipeptide and SM1213 on lymphocyte and macrophage proliferation and activation in vitro. Int J Immunopharmacol. 1979;1(1):17–27. doi: 10.1016/0192-0561(79)90026-2. [DOI] [PubMed] [Google Scholar]
  11. Juy D., Chedid L. Comparison between macrophage activation and enhancement of nonspecific resistance to tumors by mycobacterial immunoadjuvants. Proc Natl Acad Sci U S A. 1975 Oct;72(10):4105–4109. doi: 10.1073/pnas.72.10.4105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Karnovsky M. L., Lazdins J. K. Biochemical criteria for activated macrophages. J Immunol. 1978 Sep;121(3):809–813. [PubMed] [Google Scholar]
  13. Kireszenbaum F., Ferraresi R. W. Enhancement of host resistance against Trypanosoma cruzi infection by the immunoregulatory agent muramyl dipeptide. Infect Immun. 1979 Jul;25(1):273–278. doi: 10.1128/iai.25.1.273-278.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Leclerc C., Juy D., Bourgeois E., Chedid L. In vivo regulation of humoral and cellular immune responses of mice by a synthetic adjuvant, N-acetyl-muramyl-L-alanyl-D-isoglutamine, muramyl dipeptide for MDP. Cell Immunol. 1979 Jun;45(1):199–206. doi: 10.1016/0008-8749(79)90377-0. [DOI] [PubMed] [Google Scholar]
  15. Leclerc C., Juy D., Chedid L. Inhibitory and stimulatory effects of a synthetic glycopeptide (MDP) on the in vitro PFC response: factors affecting the response. Cell Immunol. 1979 Feb;42(2):336–343. doi: 10.1016/0008-8749(79)90199-0. [DOI] [PubMed] [Google Scholar]
  16. Leclerc C., Löwy I., Chedid L. Influence of MDP and of some analogous synthetic glycopeptides on the in vitro mouse spleen cell viability and immune response to sheep erythrocytes. Cell Immunol. 1978 Jul;38(2):286–293. doi: 10.1016/0008-8749(78)90059-x. [DOI] [PubMed] [Google Scholar]
  17. Löwy I., Bona C., Chedid L. Target cells for the activity of a synthetic adjuvant: muramyl dipeptide. Cell Immunol. 1977 Mar 1;29(1):195–199. doi: 10.1016/0008-8749(77)90288-x. [DOI] [PubMed] [Google Scholar]
  18. MACKANESS G. B. Cellular resistance to infection. J Exp Med. 1962 Sep 1;116:381–406. doi: 10.1084/jem.116.3.381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Mackaness G. B. The influence of immunologically committed lymphoid cells on macrophage activity in vivo. J Exp Med. 1969 May 1;129(5):973–992. doi: 10.1084/jem.129.5.973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Merser C., Sinay P., Adam A. Total synthesis and adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun. 1975 Oct 27;66(4):1316–1322. doi: 10.1016/0006-291x(75)90503-3. [DOI] [PubMed] [Google Scholar]
  21. Nagao S., Tanaka A., Yamamoto Y., Koga T., Onoue K., Shiba T., Kusumoto K., Kotani S. Inhibition of macrophage migration by muramyl peptides. Infect Immun. 1979 May;24(2):308–312. doi: 10.1128/iai.24.2.308-312.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. North R. J. Cellular kinetics associated with the development of acquired cellular resistance. J Exp Med. 1969 Aug 1;130(2):299–314. doi: 10.1084/jem.130.2.299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Parant M., Parant F., Chedid L. Enhancement of the neonate's nonspecific immunity to Klebsiella infection by muramyl dipeptide, a synthetic immunoadjuvant. Proc Natl Acad Sci U S A. 1978 Jul;75(7):3395–3399. doi: 10.1073/pnas.75.7.3395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Prunet J., Birrien J. L., Panijel J., Liacopoulos P. On the mechanism of early recovery of specifically depleted lymphoid cell populations by nonspecific activation of T cells. Cell Immunol. 1978 Apr;37(1):151–161. doi: 10.1016/0008-8749(78)90183-1. [DOI] [PubMed] [Google Scholar]
  25. Specter S., Friedman H., Chedid L. Dissociation between the adjuvant vs mitogenic activity of a synthetic muramyl dipeptide for murine splenocytes. Proc Soc Exp Biol Med. 1977 Jul;155(3):349–352. doi: 10.3181/00379727-155-39804. [DOI] [PubMed] [Google Scholar]
  26. Takada H., Tsujimoto M., Kato K., Kotani S., Kusumoto S., Inage M., Shiba T., Yano I., Kawata S., Yokogawa K. Macrophage activation by bacterial cell walls and related synthetic compounds. Infect Immun. 1979 Jul;25(1):48–53. doi: 10.1128/iai.25.1.48-53.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Taniyama T., Holden H. T. Direct augmentation of cytolytic activity of tumor-derived macrophages and macrophage cell lines by muramyl dipeptide. Cell Immunol. 1979 Dec;48(2):369–374. doi: 10.1016/0008-8749(79)90131-x. [DOI] [PubMed] [Google Scholar]
  28. Wahl S. M., Wahl L. M., McCarthy J. B., Chedid L., Mergenhagen S. E. Macrophage activation by mycobacterial water soluble compounds and synthetic muramyl dipeptide. J Immunol. 1979 Jun;122(6):2226–2231. [PubMed] [Google Scholar]
  29. Wing E. J., Gardner I. D., Ryning F. W., Remington J. S. Dissociation of effector functions in populations of activated macrophages. Nature. 1977 Aug 18;268(5621):642–644. doi: 10.1038/268642a0. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES